Rosa M. Álvarez

521 total citations
16 papers, 286 citations indexed

About

Rosa M. Álvarez is a scholar working on Organic Chemistry, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Rosa M. Álvarez has authored 16 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Organic Chemistry, 10 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Rosa M. Álvarez's work include Quinazolinone synthesis and applications (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Synthesis and biological activity (4 papers). Rosa M. Álvarez is often cited by papers focused on Quinazolinone synthesis and applications (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Synthesis and biological activity (4 papers). Rosa M. Álvarez collaborates with scholars based in Spain, Belgium and United States. Rosa M. Álvarez's co-authors include Joaquı́n Pastor, Sonia Martı́nez, José Ignacio Andrés, Jesús Alcázar, Julen Oyarzábal, Javier Fernández, Ana Isabel de Lucas, María I. Albarrán, José M. Cid and Margot H.M. Bakker and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Annals of Oncology.

In The Last Decade

Rosa M. Álvarez

16 papers receiving 275 citations

Peers

Countries citing papers authored by Rosa M. Álvarez

Since Specialization

Citations

This map shows the geographic impact of Rosa M. Álvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa M. Álvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa M. Álvarez more than expected).

Fields of papers citing papers by Rosa M. Álvarez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa M. Álvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa M. Álvarez. The network helps show where Rosa M. Álvarez may publish in the future.

Co-authorship network of co-authors of Rosa M. Álvarez

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa M. Álvarez. A scholar is included among the top collaborators of Rosa M. Álvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa M. Álvarez. Rosa M. Álvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas 2023 ·Annals of Oncology ·Robin L. Jones, Roberta Sanfilippo, Scott M. Schuetze, Ana Sebio, Rosa M. Álvarez, Nam Q. Bui, Andrew J. Wagner, (unknown), (unknown), Daniel Pink, Axel Le Cesne, Antoîne Italiano, Bruno Vincenzi, (unknown), (unknown), Richard Bryce, Feng Xu, Robert C. Doebele, Gary N. Schwartz, Mrinal M. Gounder	5
2	Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors 2021 ·ACS Medicinal Chemistry Letters ·Sonia Martı́nez, Rosa M. Álvarez, J. I. Martı́n, Ana Belén Garcı́a, (unknown), (unknown), (unknown), (unknown), María I. Albarrán, Elena Gómez‐Casero, Antonio Cebriá, Enara Aguirre, Nuria Ajenjo, David Cebrián, (unknown), (unknown), Michael F. O‘Neill, Harish P. Dave, Carmen Blanco‐Aparicio, Joaquı́n Pastor	10
3	Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors 2020 ·European Journal of Medicinal Chemistry ·Rosa M. Álvarez, Ana Belén Garcı́a, (unknown), J. I. Martı́n, (unknown), (unknown), (unknown), Julen Oyarzábal, (unknown), (unknown), María I. Albarrán, Antonio Cebriá, David Cebrián, Sonia Martı́nez, Carmen Blanco‐Aparicio, Joaquı́n Pastor	18
4	Identification of novel PI3K inhibitors through a scaffold hopping strategy 2017 ·Bioorganic & Medicinal Chemistry Letters ·Sonia Martı́nez, Ana Isabel Hernández, Rosa M. Álvarez, Antonio Rodrı́guez, (unknown), James R. Bischoff, María I. Albarrán, Antonio Cebriá, (unknown), (unknown), David Cebrián, Carmen Blanco‐Aparicio, Joaquı́n Pastor	6
5	Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy 2017 ·Bioorganic & Medicinal Chemistry Letters ·Sonia Martı́nez, (unknown), Ana Isabel Hernández, (unknown), (unknown), Rosa M. Álvarez, (unknown), James R. Bischoff, María I. Albarrán, Antonio Cebriá, (unknown), David Cebrián, Patricia Alfonso, Joaquı́n Pastor	7
6	Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors. 2013 ·Molecular Cancer Therapeutics ·Carmen Blanco‐Aparicio, Oliver Renner, Elena Gómez‐Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, (unknown), (unknown), (unknown), (unknown), Ana Belén Garcı́a, Rosa M. Álvarez, Michael F. O‘Neill, Sonia Martı́nez, Joaquı́n Pastor	2
7	Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·Joaquı́n Pastor, Julen Oyarzábal, (unknown), Rosa M. Álvarez, Virginia Rivero‐Buceta, Francisco Javier Ramos, (unknown), Carmen Blanco‐Aparicio, Nuria Ajenjo, Antonio Cebriá, María I. Albarrán, David Cebrián, (unknown), Jesús Fominaya, Guillermo Montoya, Marco Mazzorana	35
8	Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors 2012 ·PLoS ONE ·(unknown), María I. Albarrán, Rosa M. Álvarez, Obdulia Rabal, Miguel Á. Ortega, Carmen Blanco‐Aparicio, Guido Kurz, Antonio Salgado, Paolo Pevarello, James R. Bischoff, Joaquı́n Pastor, Julen Oyarzábal	19
9	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·Sonia Martı́nez, Ana Isabel Hernández, (unknown), (unknown), Rosa M. Álvarez, Ana Belén Garcı́a, (unknown), Virginia Rivero‐Buceta, Julen Oyarzábal, Obdulia Rabal, James R. Bischoff, María I. Albarrán, Antonio Cebriá, Patricia Alfonso, Wolfgang Link, Jesús Fominaya, Joaquı́n Pastor	26
10	Novel Approach for Chemotype Hopping Based on Annotated Databases of Chemically Feasible Fragments and a Prospective Case Study: New Melanin Concentrating Hormone Antagonists 2009 ·Journal of Medicinal Chemistry ·Julen Oyarzábal, Trevor Howe, Jesús Alcázar, José Ignacio Andrés, Rosa M. Álvarez, Frank M. Dautzenberg, Laura Iturrino, Sonia Martı́nez, Ilse Van der Linden	23
11	Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism 2007 ·Bioorganic & Medicinal Chemistry ·José Ignacio Andrés, Jesús Alcázar, José Manuel Alonso Segura, Rosa M. Álvarez, Margot H.M. Bakker, (unknown), José M. Cid, Ana Isabel de Lucas, Wilhelmus Drinkenburg, Javier Fernández, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	28
12	4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective δ-opioid agonists with potential anxiolytic/antidepressant properties. Part 2 2007 ·Bioorganic & Medicinal Chemistry Letters ·Andrés A. Trabanco, (unknown), Rosa M. Álvarez, José Ignacio Andrés, (unknown), Javier Fernández, Antonio Bermejo Gómez, Frans Janssens, (unknown), Ana Isabel de Lucas, (unknown), Thomas Steckler, Shirley Pullan	19
13	4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·Andrés A. Trabanco, Shirley Pullan, José Manuel Alonso Segura, Rosa M. Álvarez, José Ignacio Andrés, (unknown), Javier Fernández, Antonio Bermejo Gómez, Laura Iturrino, Frans Janssens, (unknown), Ana Isabel de Lucas, (unknown), Theo Meert, Thomas Steckler	5
14	Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety 2004 ·Bioorganic & Medicinal Chemistry Letters ·Joaquı́n Pastor, Jesús Alcázar, Rosa M. Álvarez, José Ignacio Andrés, José M. Cid, Ana Isabel de Lucas, (unknown), Javier Fernández, (unknown), Laura Iturrino, (unknown), Sonia Martı́nez, Margot H.M. Bakker, (unknown), Lieve Heylen, Anton A. H. P. Megens	17
15	Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α₂-Adrenoceptor Blocking Activity 2004 ·Journal of Medicinal Chemistry ·José Ignacio Andrés, Jesús Alcázar, José Manuel Alonso Segura, Rosa M. Álvarez, Margot H.M. Bakker, (unknown), José M. Cid, Ana Isabel de Lucas, Javier Fernández, (unknown), (unknown), Laura Iturrino, Ilse Lenaerts, Sonia Martı́nez, Anton Megens, Joaquı́n Pastor, (unknown), Thomas Steckler	43
16	Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities: a novel series of potential antidepressants 2003 ·Bioorganic & Medicinal Chemistry Letters ·José Ignacio Andrés, Jesús Alcázar, José Manuel Alonso Segura, Rosa M. Álvarez, José M. Cid, Ana Isabel de Lucas, Javier Fernández, Sonia Martı́nez, Carmen Nieto, Joaquı́n Pastor, Margot H.M. Bakker, (unknown), Lieve Heylen, Anton Megens	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact